
MoonLake Immunotherapeutics AG (NASDAQ:MLTX) dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis suppurativa (HS).
Initiation of this Phase 2 trial follows the approval of trial protocol obtained from the central Institutional Review Board, that supported IND filing with the regulatory agency.